InMed’s CEO, Eric A. Adams, speaks with The Dales Report’s Shadd Dales and Anthony Varrell about the company’s recent Alzheimer’s disease in vivo studies. He talks about current amyloid-beta treatments for Alzheimer’s as well as the need for new treatments to address the multiple pathologies related to this disease, including neuroinflammation.
Eric Adams also talks about how cannabinoids can naturally cross the blood brain barrier, making them promising therapeutic targets for neurodegenerative diseases like Alzheimer’s disease. He speaks about InMed’s non-intoxicating cannabinoid analogs and how InMed’s Alzheimer’s disease drug candidate, INM-901, has demonstrated it activates CB1, CB2 and PPAR receptors.
You can also watch The Dales Report podcast interview on YouTube here.
